Patient Assistance Program. Client specific
Patient Assistance Program. Nova Factor shall develop and administer a patient assistance program in accordance with applicable law and regulations to assist patients financially unable to afford Genentech HGH therapy; provided, however, that Nova Factor shall not have any obligation related to patients having no third party payer coverage for Genentech HGH therapy as described in Section 3.2(b), which patients may be eligible for Genentech's Uninsured Patients Program. Nova Factor shall develop its own financial criteria for patients and shall review each patient's financial status on a case-by-case basis, all in conformance with applicable laws, rules and regulations.
Patient Assistance Program. AstraZeneca shall have the right for [***] after the Effective Date to supply Licensed Product through its patient assistance program, at its own cost. After such [***] period, Impax shall have the right but not the obligation to establish a patient assistance program to supply Licensed Product, at its own cost, and AstraZeneca shall at Impax’ request reasonably cooperate with Impax in Impax’ efforts to establish a patient assistance program for the Existing Products with the Third Party that AstraZeneca is currently utilizing to manage AstraZeneca’s patient assistance program for the Existing Products in the Territory.
Patient Assistance Program. A patient assistance program may provide financial, educational or other assistance to you or your dependents with respect to certain services or supplies. If you or your dependents are eligible for a patient assistance program, Great-West Life can require you or your dependent to apply to and participate in such a program. Where financial assistance is available from a patient assistance program in which Great-West Life requires participation, Great-West Life can reduce the amount of a covered expense for a service or supply by the amount of financial assistance you or your dependent is entitled to receive for that service or supply. How to Make a Claim Out-of-country claims (including those for Global Medical Assistance expenses) should be submitted to Great-West Life as soon as possible after the expense is incurred. It is very important that you send your claims to the Great-West Life Out-of-Country Claims Department immediately as your Provincial or Territorial Medical Plan has very strict time limitations. Access GroupNet for Plan Members to obtain a personalized claim form or obtain form M5432 (Statement of Claim Out-of-Country Expenses form) from your employer. You must also obtain the Government Assignment form, and residents of British Columbia, Quebec and Newfoundland & Labrador must also obtain the Special Government Claim form. The Great-West Life Out-of-Country Claims Department will forward the appropriate government forms to your attention when required. You should complete all applicable forms, making sure all required information is included. Attach all original receipts and forward the claim to the Great-West Life Out-of-Country Claims Department. Be sure to keep a copy for your own records. The plan will pay all eligible claims including your Provincial or Territorial Medical Plan portion. Your Provincial or Territorial Medical Plan will then reimburse the plan for the government’s share of the expenses. Out-of-country claims must be submitted within a certain time period that varies by province or territory. For the claims submission period applicable in your province or territory or for any other questions or for assistance in completing any of the forms, please contact Great-West Life’s Out-of- Country Claims Department at 1-800-957-9777. Claims for expenses incurred in Canada, for paramedical services and visioncare, may be submitted online. To use this online service you will need to be registered for GroupNet for Plan Members ...
Patient Assistance Program. In addition to the distribution and other services described in this Agreement, Distributor agrees to distribute the Product associated with patients enrolled in QLT’s patient assistance program (“PAP”). QLT administers the PAP through a third party service provider, as identified by QLT from time to time (the “PAP Provider”). Upon notification from the PAP Provider, Distributor agrees to promptly ship the Product to medical practitioners for use with PAP patients in accordance with the instructions received from the PAP Provider [*]. Notwithstanding Section 4.8, the practitioner receiving the Product pursuant to the PAP shall be considered an “Approved Customer” hereunder solely for purposes of the PAP, [*]. Following distribution of the Product, Distributor shall report to QLT the amount of such Product distributed to practitioners for PAP patients and QLT shall then ship replacement Product to Distributor [*] to replace the Product distributed to practitioners for PAP patients.
Patient Assistance Program. Seller shall be responsible for all patient assistance programs with respect to Products dispensed to patients prior to the Closing Date. Seller shall terminate all patient assistance programs with respect to the Products effective as of the Closing Date.
Patient Assistance Program. 3.9.1 Client may contract with, or has contracted with, or sponsors a foundation or organization (“Organization”) that offers eligibility services for free Product to individuals who have no insurance coverage or financial means to cover all or part of the full cost of the Product (the “Patient Assistance Program”). [***]
Patient Assistance Program. The following provision is added to the Termination Agreement as Paragraph 10:
Patient Assistance Program. NPDC shall establish within one year (1) after the first commercial sale of the LHRH Implant in the United States for the treatment of prostate cancer, and maintain for a period ending on the earlier of (a) ten (10) years after establishment or (b) the cessation of marketing of the LHRH Implant in the United States for the treatment of prostate cancer (the "Patient Assistance Program Period"), a patient assistance program substantially similar to the program described in Exhibit C hereto. During the Patient Assistance Program Period, within one hundred and twenty (120) days after the conclusion of each calendar year, NPDC shall furnish to The Council a report showing the total number of LHRH Implants that were sold in the United States in the preceding year and the total number of LHRH Implants that were distributed to patients through the Patient Assistant Program in such preceding year.
Patient Assistance Program. Profile agrees to participate with CoTherix in the Ventavis Patient Assistance Program (“PAP”) by providing Prodose Devices (and when available I-Nebs) and Consumables free of charge to patients who qualify for such program (which shall not exceed [***] of the total number of patients at any given time on Ventavis AAD therapy). To be eligible for the PAP, and to remain eligible for participation in the PAP, patients must: (i) be US citizens; (ii) not possess, and not obtain during the course of treatment, medical insurance; and (iii) meet, and continue to meet at all times during participation in the PAP, certain eligibility criteria developed by CoTherix concerning financial hardship (to be determined by objective factors that are similar in scope to those used for similar programs), such eligibility criteria to be approved by Profile, with Profile’s approval not to be unreasonably withheld. PAP patients will also receive Ventavis at no charge and will received reduced service fees from the Specialty Pharmacy Company. CoTherix or the Specialty Pharmacy Company will provide Profile with monthly written reports on the number of patients then on Ventavis AAD therapy and the number of patients participating in the PAP. Each PAP Patient shall be provided with two (2) Prodose Devices (and when available, 2 I-Nebs) and the related Consumables needed to operate such AAD Devices, with the frequency of replacement of AAD Devices and Consumables being consistent with the frequency of replacement for non-PAP patients. If at any time during a patient’s participation in the PAP, the patient becomes ineligible for further participation, the Specialty Pharmacy Company must return to Profile both AAD Devices that had been in the possession of such patient or pay Profile for such AAD Devices at the price set forth in Section 6.1 above.
